---
title: "U.S. FDA: Seeks to remove suicide warning from GLP-1 drugs"
description: "The U.S. FDA has requested the removal of suicide warnings from GLP-1 medications, believing that these drugs do not increase the risk of suicidal tendencies. The affected medications include Novo Nor"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/272427531.md"
published_at: "2026-01-13T14:23:47.000Z"
---

# U.S. FDA: Seeks to remove suicide warning from GLP-1 drugs

> The U.S. FDA has requested the removal of suicide warnings from GLP-1 medications, believing that these drugs do not increase the risk of suicidal tendencies. The affected medications include Novo Nordisk's Wegovy, Saxenda, and Eli Lilly's Zepbound. The FDA's review was based on 91 trials involving 107,910 patients, with results showing no increased risk of suicidal thoughts or behaviors. A UK investigation also found no association between weight loss drugs and suicide

The U.S. Food and Drug Administration (FDA) stated that it requires the removal of warnings regarding the exacerbation of "suicidal behavior" (SI/B) from a range of GLP-1 medications. The FDA found no evidence that the use of these drugs increases the risk of SI/B. The affected medications are Novo Nordisk's Wegovy, Saxenda, and Eli Lilly's Zepbound.

The FDA's review covered 91 placebo-controlled trials involving 107,910 patients; the results showed that the risk of suicidal thoughts or behaviors did not increase.

Previously, a survey in the UK also found no evidence of a link between weight loss drugs and suicide

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| GLP-1 drugs may cause scurvy in patients | GLP-1 weight loss drugs, including Ozempic and Wegovy, are linked to cases of scurvy, a rare illness caused by vitamin C | [Link](https://longbridge.com/en/news/275772745.md) |
| GLP-1 Anti-Obesity U.S. Drug Market In Four Charts | UBS analysts, led by Matthew Weston, have analyzed trends in the U.S. GLP-1 anti-obesity drug market, focusing on new-to | [Link](https://longbridge.com/en/news/276280378.md) |
| FDA issues emergency use authorizations for drugs to treat New World screwworm in dogs and cats | FDA issues emergency use authorizations for drugs to treat New World screwworm in dogs and cats | [Link](https://longbridge.com/en/news/276265729.md) |
| 10:54 ETMeijer anuncia un nuevo acceso asequible a medicamentos GLP-1 | Meijer has announced a new initiative to make GLP-1 medications, Wegovy® and Ozempic®, more affordable for customers in  | [Link](https://longbridge.com/en/news/275484824.md) |
| Forget AI stocks: This pharma giant is using AI to dominate drug discovery | And there's more than one way to monetize this technology. | [Link](https://longbridge.com/en/news/276017486.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.